[go: up one dir, main page]

PE20051136A1 - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
PE20051136A1
PE20051136A1 PE2005000079A PE2005000079A PE20051136A1 PE 20051136 A1 PE20051136 A1 PE 20051136A1 PE 2005000079 A PE2005000079 A PE 2005000079A PE 2005000079 A PE2005000079 A PE 2005000079A PE 20051136 A1 PE20051136 A1 PE 20051136A1
Authority
PE
Peru
Prior art keywords
hydroxy
phenyl
amino
alkyl
methylpropyl
Prior art date
Application number
PE2005000079A
Other languages
English (en)
Inventor
Alan Daniel Brown
Mark Edward Bunnage
Kim James
Russell Andrew Lewthwaite
Nicholas Murray Thomson
David Anthony Price
Ian Brian Moses
Charlotte Alice Louise Lane
Paul Alan Glossop
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20051136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20051136A1 publication Critical patent/PE20051136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE EL GRUPO (CH2)n-C(=O)Q1 ESTA EN POSICION META O PARA, R1 Y R2 SON CADA UNO H, ALQUILO C1-C4; n ES 0-2; Q1 ES (a), (b) O UN GRUPO *-NR8-Q2-A DONDE p ES 1-2; Q2 ES ALQUILENO C1-C4; R8 ES H, ALQUILO C1-C4; A ES PIRIDILO, CICLOALQUILO C3-C7, OPCIONALMENTE SUSTITUIDOS; R3, R4, R5, R6 SON CADA UNO H, ALQUILO C1-C4, ENTRE OTROS; * ES EL PUNTO DE UNION AL CARBONILO. TAMBIEN REFERIDA A UN PROCEDIMIENTO PARA LA PREPARACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 2-(3-{2-[((2R)-2-HIDROXI-2-{4-HIDROXI-3-[(METILSULFONIL)AMINO]FENIL}ETIL)AMINO]-2-METILPROPIL}FENIL)-N-(4-HIDROXI-3-METOXIBENCIL)ACETAMIDA; N-[(3'-HIDROXIBIFENIL-2-IL)METIL]-2-(3-{2-[((2R)-2-HIDROXI-2-{4-HIDROXI-3-[(METILSULFONIL)AMINO]FENIL}ETIL)AMINO]-2-METILPROPIL}FENIL)ACETAMIDA; ENTRE OTROS. DICHOS COMPUESTOS CON ACTIVIDAD AGONISTA B2 SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS COMO BRONQUITIS, DANO AGUDO DE PULMON, BRONQUIECTASIA, ENTRE OTROS
PE2005000079A 2004-01-22 2005-01-20 Derivados de sulfonamida PE20051136A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09

Publications (1)

Publication Number Publication Date
PE20051136A1 true PE20051136A1 (es) 2006-02-18

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000079A PE20051136A1 (es) 2004-01-22 2005-01-20 Derivados de sulfonamida

Country Status (30)

Country Link
US (4) US7244766B2 (es)
EP (1) EP1708991B1 (es)
JP (1) JP4020954B2 (es)
AP (1) AP2359A (es)
AR (1) AR047509A1 (es)
AT (1) ATE375977T1 (es)
AU (1) AU2005214153B2 (es)
BR (1) BRPI0507085A (es)
CA (1) CA2553789C (es)
DE (1) DE602005002930T2 (es)
DK (1) DK1708991T3 (es)
DO (1) DOP2005000006A (es)
EA (1) EA011167B1 (es)
ES (1) ES2293530T3 (es)
GE (1) GEP20094781B (es)
MY (1) MY143390A (es)
NL (1) NL1028087C2 (es)
NO (1) NO20062983L (es)
NZ (1) NZ548318A (es)
OA (1) OA13362A (es)
PA (1) PA8622001A1 (es)
PE (1) PE20051136A1 (es)
PL (1) PL1708991T3 (es)
PT (1) PT1708991E (es)
RS (1) RS50561B (es)
SI (1) SI1708991T1 (es)
TW (1) TWI341831B (es)
UA (1) UA84048C2 (es)
UY (1) UY28721A1 (es)
WO (1) WO2005080313A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548318A (en) * 2004-01-22 2009-03-31 Pfizer Sulfonamide derivatives for the treatment of diseases
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
CN101223132A (zh) * 2005-07-18 2008-07-16 辉瑞有限公司 制备磺酰胺衍生物的方法
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
WO2013021309A1 (en) 2011-08-11 2013-02-14 Pfizer Limited Intermediate and process for the preparation of a sulfonamide derivative
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US229058A (en) * 1880-06-22 spencer
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR20010014183A (ko) 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US20030185700A1 (en) * 2002-03-26 2003-10-02 The Japan Steel Works, Ltd. Heat-resisting steel and method of manufacturing the same
JP2005527618A (ja) * 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
NZ548318A (en) * 2004-01-22 2009-03-31 Pfizer Sulfonamide derivatives for the treatment of diseases

Also Published As

Publication number Publication date
US20100273758A1 (en) 2010-10-28
UA84048C2 (ru) 2008-09-10
WO2005080313A3 (en) 2005-12-01
AP2006003669A0 (en) 2006-06-30
US7528170B2 (en) 2009-05-05
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17
US20090197912A1 (en) 2009-08-06
MY143390A (en) 2011-05-13
NL1028087C2 (nl) 2006-05-09
AU2005214153B2 (en) 2008-09-18
WO2005080313A9 (en) 2006-08-31
EA200601223A1 (ru) 2006-12-29
JP4020954B2 (ja) 2007-12-12
US7767715B2 (en) 2010-08-03
PL1708991T3 (pl) 2008-02-29
AP2359A (en) 2012-01-30
DOP2005000006A (es) 2005-07-31
CA2553789C (en) 2011-07-19
EA011167B1 (ru) 2009-02-27
ATE375977T1 (de) 2007-11-15
WO2005080313A2 (en) 2005-09-01
DE602005002930T2 (de) 2008-07-24
CA2553789A1 (en) 2005-09-01
AU2005214153A1 (en) 2005-09-01
BRPI0507085A (pt) 2007-06-19
NL1028087A1 (nl) 2005-07-25
TW200530165A (en) 2005-09-16
UY28721A1 (es) 2005-08-31
PT1708991E (pt) 2007-12-14
US20080267970A1 (en) 2008-10-30
PA8622001A1 (es) 2005-08-30
US20050182091A1 (en) 2005-08-18
DK1708991T3 (da) 2008-01-14
NO20062983L (no) 2006-07-24
GEP20094781B (en) 2009-09-25
OA13362A (en) 2007-04-13
JP2007518789A (ja) 2007-07-12
SI1708991T1 (sl) 2008-02-29
RS50561B (sr) 2010-05-07
DE602005002930D1 (de) 2007-11-29
EP1708991B1 (en) 2007-10-17
EP1708991A2 (en) 2006-10-11
ES2293530T3 (es) 2008-03-16
AR047509A1 (es) 2006-01-25
US8013019B2 (en) 2011-09-06
TWI341831B (en) 2011-05-11

Similar Documents

Publication Publication Date Title
PE20051136A1 (es) Derivados de sulfonamida
PE20050765A1 (es) DERIVADOS DE SULFONAMIDA COMO AGONISTAS DE LOS RECEPTORES ß2 ADRENERGICOS
PE20090641A1 (es) Amidas heterociclicas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20090727A1 (es) DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7
PE20091408A1 (es) Compuestos y composiciones como inhibidores de cinasa
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
AR066273A1 (es) Agentes anti- hipertensivos de accion dual
EA200800781A1 (ru) АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
RU2008107727A (ru) Макроциклические ингибиторы вируса гепатита с
RU2008112683A (ru) Ингибиторы fap
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
DK526188A (da) Benzimidazolin-2-oxo-1-carboxylsyrederivater til anvendelse som 5-ht receptorantagonister i farmaceutiske praeparater
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
PE20060095A1 (es) Agonistas beta 2 y procesos para su preparacion
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed